Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 10/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12168148 | 0.87 | HCAR2 (0.59) | MAPK1HCAR2DAOHCAR3CYTH3 | |
| SCHEMBL1815487 | 0.87 | MAPK1 (0.48) | MAPK1HCAR2DAOHCAR3ALPL | |
| SCHEMBL13279353 | 0.85 | MAPK1 (0.47) | MAPK1HCAR2DAOMMEHCAR3 | |
| SCHEMBL17672394 | 0.82 | MAPK1 (0.79) | MAPK1HCAR2MAPTALPL | |
| SCHEMBL21608068 | 0.82 | CHEK1 (0.54) | MAPK1HCAR2DAOMME | |
| SCHEMBL1812854 | 0.82 | MAPK1 (0.79) | MAPK1MAPTALPL | |
| SCHEMBL1312019 | 0.78 | MAPK1 (0.53) | MAPK1MAPTALPL | |
| SCHEMBL15059496 | 0.78 | MAPK1 (0.53) | MAPK1HCAR2DAOMMEALDH1A1 | |
| SCHEMBL12092824 | 0.78 | ALPL (0.54) | MAPK1ALDH1A1KDM4EMAPTALPL | |
| SCHEMBL26449929 | 0.78 | ALPL (0.45) | MAPK1MMEALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2021189051-A1 | ANDROGEN RECEPTOR REGULATION BY SMALL MOLECULE ENANTIOMERS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2021-09-23 | — | — | WO | disclosed |
| EP-3280710-B1 | PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF | ORION CORP (FI) | 2020-02-26 | — | — | EP | disclosed |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-8642554-B2 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | MAPK1 920/4885HCAR2 75/4885DAO 1338/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | MAPK1 1759/4885HCAR2 2637/4885DAO 1306/4885 |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | BID, BAD, BIRC3 | MAPK1 3289/4885HCAR2 2915/4885DAO 4558/4885 |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | BID, BAD, BIRC3 | MAPK1 3289/4885HCAR2 2915/4885DAO 4558/4885 |
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | MAPK1 807/4885HCAR2 300/4885DAO 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.